Sarina Tanimoto compensation by year
ARS Pharmaceuticals Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $70,893 | $473,300 | $501,698 | $540,000 |
| Bonus | $0 | $0 | $0 | — |
| Stock awards | $0 | $0 | $0 | — |
| Option awards | $0 | $2,320,500 | $1,309,800 | $2,107,247 |
| Non-equity incentive | $153,144 | $132,524 | $260,880 | $178,200 |
| Pension and deferred compensation | $0 | $0 | $0 | — |
| All other | $114,110 | $1,865,169 | $2,174,395 | $2,465,024 |
| Total | $338,147 | $4,791,493 | $4,246,773 | $5,290,471 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARS Pharmaceuticals, Inc. DEF 14A filed April 29, 2026, accession 0001193125-26-191433, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ARS Pharmaceuticals, Inc. filed document, accession 0001193125-26-191433. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 94,792 | — | $8.42 |
| Option | 156,250 | — | $5.58 |
| Option | 201,882 | — | $10.71 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ARS Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
ARS Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Richard Lowenthal | President and Chief Executive Officer | $9,656,400 |
| Sarina Tanimoto · this page | Chief Medical Officer | $5,290,471 |
| Justin Chakma | Chief Business Officer | $2,888,109 |
Sarina Tanimoto's compensation dossier, ARS Pharmaceuticals
You have read Sarina Tanimoto's totals and holdings. The dossier adds each equity grant ARS Pharmaceuticals disclosed for Sarina Tanimoto and ARS Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full ARS Pharmaceuticals compensation record
free company briefThis page is one person within ARS Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ARS Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ARS Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARS Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order SPRY
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.